[BNP in HIV-infected Patients]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2009 Dec 22

PMID 20024643

Citations 6

Authors

Till Neumann

Nico Reinsch

Kathrin Neuhaus

Norbert Brockmeyer

Anja Potthoff

Stefan Esser

Martin Hower

Anja Neumann

Sarah Mostardt

Gotz Gelbrich

Raimund Erbel

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: HIV-infected patients exhibit an increased rate of cardiac diseases, due to an elevated rate of cardiac risk factors and side effects of antiretroviral therapy. The aim of the present study was to analyze the impact of B-type natriuretic peptide (BNP) in this patient population.

Patients And Methods: The HIV-HEART (HIV infection and HEART disease) study is a prospective and multicenter cohort study. Outpatients with a known HIV infection were included over a 20-month recruiting period. BNP values were determined by a standardized laboratory test at study inclusion.

Results: 802 HIV-infected patients (male: 83.4%, mean age: 44.2 +/- 10.3 years) were included. The BNP concentrations (median 11.3 pg/ml; BNP < or = 100 pg/ml: 96.2%) were associated with echocardiographic parameters and with the right ventricular diameter (p = 0.02) and the systolic pulmonary arterial pressure (p = 0.01). Patients with a BNP concentration of > 50 pg/ml had a significantly higher rate of heart failure (p < 0.001), cardiomyopathy (p < 0.001), and coronary artery disease (p < 0.001).

Conclusion: The data demonstrate that BNP is suitable for the detection of cardiac disorders in HIV-infected subjects. Therefore, BNP could be an appropriate tool for a screening program for HIV-associated disorders in this patient population.

Citing Articles

Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015.

Masia M, Padilla S, Garcia J, Garcia-Abellan J, Fernandez M, Bernardino I PLoS One. 2019; 14(4):e0215507.

PMID: 31026289 PMC: 6485642. DOI: 10.1371/journal.pone.0215507.

Elevated NT-pro-brain natriuretic peptide level is independently associated with all-cause mortality in HIV-infected women in the early and recent HAART eras in the Women's Interagency HIV Study cohort.

Gingo M, Zhang Y, Ghebrehawariat K, Jeong J, Chu Y, Yang Q PLoS One. 2015; 10(3):e0123389.

PMID: 25811188 PMC: 4374715. DOI: 10.1371/journal.pone.0123389.

[Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies].

Neumann T, Lulsdorf K, Krings P, Reinsch N, Erbel R Herz. 2010; 36(1):18-23.

PMID: 21181097 DOI: 10.1007/s00059-010-3410-7.

Biomarker and no end to it?.

Maisch B Herz. 2009; 34(8):579-80.

PMID: 20024635 DOI: 10.1007/s00059-009-3319-1.

Plant glutaredoxins: still mysterious reducing systems.

Rouhier N, Gelhaye E, Jacquot J Cell Mol Life Sci. 2004; 61(11):1266-77.

PMID: 15170506 PMC: 11138834. DOI: 10.1007/s00018-004-3410-y.

References

Lainscak M, Anker S . Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz. 2009; 34(2):141-7. DOI: 10.1007/s00059-009-3211-z. View

Jacob A, Boon N . HIV cardiomyopathy: a dark cloud with a silver lining?. Br Heart J. 1991; 66(1):1-2. PMC: 1024553. DOI: 10.1136/hrt.66.1.1. View

Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S . Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009; 361(9):858-67. DOI: 10.1056/NEJMoa0900428. View

Neumann T, Kondratieva J, Breuckmann F, Erbel R . [HIV-associated cardiomyopathy]. Herz. 2005; 30(6):545-9. DOI: 10.1007/s00059-005-2729-y. View

Neumann T . [HIV, AIDS and the cardiovascular risk]. Internist (Berl). 2008; 49(4):429-30, 432-5. DOI: 10.1007/s00108-008-2049-4. View

Jurriaans S, VAN Gemen B, Weverling G, van Strijp D, Nara P, Coutinho R . The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?. Virology. 1994; 204(1):223-33. DOI: 10.1006/viro.1994.1526. View

Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F . Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007; 12(6):243-8. View

. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses. 2000; 16(12):1123-33. DOI: 10.1089/088922200414965. View

Kristoffersen U, Lebech A, Gerstoft J, Hesse B, Petersen C, Gutte H . Right and left cardiac function in HIV-infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: a 5-year follow-up study. HIV Med. 2008; 9(3):180-6. DOI: 10.1111/j.1468-1293.2007.00531.x. View

10.

Griffith B, Brett-Smith H, Kim G, Mellors J, Chacko T, Garner R . Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis. 1996; 173(5):1252-5. DOI: 10.1093/infdis/173.5.1252. View

11.

Carrillo-Jimenez R, Treadwell T, Goldfine H, Buenano A, Lamas G, Hennekens C . Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read. 2002; 12(11):501-3, 508. View

12.

Breuckmann F, Nassenstein K, Kondratieva J, Esser S, Erbel R, Potthoff A . MR characterization of cardiac abnormalities in HIV+ individuals with increased BNP levels. Eur J Med Res. 2007; 12(5):185-90. View

13.

Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G . Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007; 28(2):230-68. DOI: 10.1093/eurheartj/ehl428. View

14.

Donovan R, Bush C, Markowitz N, Baxa D, Saravolatz L . Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis. 1996; 174(2):401-3. DOI: 10.1093/infdis/174.2.401. View

15.

Frerichs F, Dingemans K, Brinkman K . Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med. 2002; 347(23):1895-6. DOI: 10.1056/NEJM200212053472320. View

16.

Simonneau G, Galie N, Rubin L, Langleben D, Seeger W, Domenighetti G . Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S):5S-12S. DOI: 10.1016/j.jacc.2004.02.037. View

17.

Felker G, Hasselblad V, Hernandez A, OConnor C . Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009; 158(3):422-30. DOI: 10.1016/j.ahj.2009.06.018. View